Drug intelligence / Profile preview

MV-αCD38

Development stage: Preclinical
Lead developer: Mayo Clinic
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intravenous

Overview

MV-αCD38 is a recombinant oncolytic measles virus (MV-Edm strain) engineered for the treatment of multiple myeloma. It is designed to specifically target CD38-expressing myeloma cells by displaying an anti-CD38 single-chain antibody (scFv) on its hemagglutinin (H) glycoprotein. This modification redirects viral entry through CD38, while the virus retains its intrinsic oncolytic activity, leading to cell-cell fusion and cytopathic effects in targeted cells. The development aims to minimize collateral damage to normal tissues by ablating binding to natural measles virus receptors like CD46 and SLAM.

Targets

CD38 (Cluster of Differentiation 38)

Beyond the preview

Go deeper on MV-αCD38.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MV-αCD38.

Explore the full profile